Investigational drug · Phase 2
F182112
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed or Refractory Multiple Myeloma.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "F182112"
First trial start
2025
Jul 2, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "F182112", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed or Refractory Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "F182112" as an intervention, largest first.
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT07579234 · 261 participants (planned) · Start Jan 25, 2026 · Primary completion Jan 25, 2029
Drug: F182112 single-agent; Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd) · For: Relapsed or Refractory Multiple Myeloma (RRMM)
Sites: Tianjing, China
- A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple MyelomaRecruiting
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT07312188 · 90 participants (planned) · Start Jul 2, 2025 · Primary completion May 20, 2028
Drug: F182112+P; F182112+CD38 · For: Relapsed or Refractory Multiple Myeloma
Sites: Tianjin, China
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT04984434 · 68 participants (planned) · Start Jul 30, 2021 · Primary completion Jul 30, 2023
Drug: F182112 · For: Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma
Sites: Linyi, China
- F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus ErythematosusRecruiting
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT07829614 · 64 participants (planned) · Start Oct 30, 2025 · Primary completion Dec 31, 2027
Drug: F182112 · For: Systemic Lupus Erythematosus (SLE)
Sites: Shanghai, China
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07816341 · 12 participants (planned) · Start Oct 27, 2026 · Primary completion Dec 31, 2027
Drug: F182112 single-agent · For: Autoimmune Hemolytic Anemia
Sites: Tianjin, China
- F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple MyelomaNot yet recruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07828522 · 10 participants (planned) · Start Oct 1, 2026 · Primary completion Oct 9, 2027
Drug: F182112 Plus Isatuximab and Lenalidomide · For: Multiple Myeloma (MM); Transplant-eligible Patients
Newest research
PubMed records naming it or its code names, newest first.
- Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J, Ren Q, Liu X, et al. · J Hematol Oncol 2023
Also in development for Relapsed or Refractory Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- QLS32015Phase 32 trials
Qilu Pharmaceutical Co., Ltd. · Relapsed or Refractory Multiple Myeloma
- QLS4131Phase 32 trials
Qilu Pharmaceutical Co., Ltd. · Malignant Plasma Cell Neoplasms, Relapsed or Refractory Multiple Myeloma
- MBS314Phase 22 trials
Beijing Mabworks Biotech Co., Ltd. · Relapsed or Refractory Multiple Myeloma, Multiple Myeloma
- AZD4045Phase 21 trial
AstraZeneca · Relapsed or Refractory Multiple Myeloma
- CD38Phase 21 trial
Shandong New Time Pharmaceutical Co., LTD · Relapsed or Refractory Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.